Eosinophil values in exacerbation and stable chronic obstructive pulmonary disease and its relationship to maintenance therapy in stable chronic obstructive pulmonary disease patients
Authors:
- Muhammad FachriMFMuhammad Fachri
- Mochammad HattaMHMochammad Hatta
- Fira Indah LestariFLFira Indah Lestari
- Risky AkaputraRARisky Akaputra
- Fatimah FatimahFFFatimah Fatimah
- Athariq WahabAWAthariq Wahab
- Yunita ArliniyYAYunita Arliniy
- Ressy DwiyantiRDRessy Dwiyanti
- Ahmad SyukriASAhmad Syukri
- Ade Rifka JunitaAJAde Rifka Junita
- Andini FebriantiAFAndini Febrianti
- Muhammad Reza PrimagunaMPMuhammad Reza Primaguna
Open Access
- 4 September 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (10) , 4799-4805
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is characterised by persistent and progressive airflow limitations. The study aimed to determine the relationship between eosinophil values in patients with stable and exacerbated COPD, and the relationship of eosinophil values with two drug regimens used as maintenance therapy in stable COPD. Materials and methods: This cross-sectional study and the variables used in this study were eosinophil counts in stable and exacerbated COPD patients. Results: Eighty-three patients with stable and exacerbated COPD were included. Stable COPD (63.9%) was predominant, with the highest degree of symptoms in group A 18 patients (34%) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2; 35 patients (66%). The degree of COPD exacerbation was dominated by Type II COPD 15 patients (50%). Eosinophil counts in patients with stable COPD were less than 100 cells/mm3 37 patients (44.6%), while in patients with COPD exacerbation, it was greater than 100 cells/mm3 with a total of 30 patients (36.1%). Long acting muscarinic antagonist class of drugs was the most used treatment as maintenance therapy in stable COPD 34 patients (64.2%). Conclusion: The eosinophil counts in patients with COPD exacerbation were significantly higher than those in patients with stable COPD. The provision of maintenance therapy in the long acting β-2 agonist + inhaled glucocorticosteroid group of stable COPD patients was generally provided to COPD patients with eosinophil values greater than 100 cells/mm3, and the provision of long-term maintenance therapy in stable COPD patients was generally given to COPD patients with eosinophil values less than 100 cells/mm3.Keywords
This publication has 26 references indexed in Scilit:
- Bronchial mucosal inflammation and illness severity in response to experimental rhinovirus infection in COPDJournal of Allergy and Clinical Immunology, 2020
- Hubungan Antara Hitung Jenis Leukosit dengan Derajat Penyakit Paru Obstruktif Kronik Berdasarkan Gejala Klinis dan Gold 2019 pada Pasien Penyakit Paru Obstruktif Kronik Stabil di Rumah Sakit Islam Jakarta SukapuraMuhammadiyah Journal of Geriatric, 2020
- Hematologic parameters in pulmonary tuberculosis patients based on the microscopic sputum examinationEnfermería Clínica, 2020
- Stability of the Blood Eosinophilic Phenotype in Stable and Exacerbated COPDChest, 2019
- Eosinophilic Chronic Obstructive Pulmonary Disease: Implications for Exacerbations, Readmissions, and TreatmentAmerican Journal of Respiratory and Critical Care Medicine, 2019
- Body mass index of patients with chronic obstructive pulmonary disease is associated with pulmonary function and exacerbations: a retrospective real world researchJournal of Thoracic Disease, 2018
- Blood eosinophil levels as a biomarker in COPDRespiratory Medicine, 2018
- Role of eosinophils in airway inflammation of chronic obstructive pulmonary diseaseInternational Journal of Chronic Obstructive Pulmonary Disease, 2018
- The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to DPulmonary Pharmacology & Therapeutics, 2015
- COPD: balancing oxidants and antioxidantsInternational Journal of Chronic Obstructive Pulmonary Disease, 2015